GEMBLOUX, Belgium, May 2024 — Full-Life Technologies Limited, a leader in the global radiotherapeutics industry, announced the appointment of Mark S. de Jong, PhD, as Chief Technical Officer (CTO). Dr. de Jong brings an impressive 43 years of leadership experience in accelerator physics and isotope production to Full-Life Technologies. He transitions to this role from Canadian Isotope Innovations Corp., where he served as Chief Technology Officer.
At Canadian Isotope Innovations, Dr. de Jong led the development and operation of the Medical Isotope Production (MIP) facility, which features a 35 MeV electron linear accelerator for medical isotope production. His work there included pioneering efforts in the development of new radioisotopes for medical applications using electron accelerators and advancing target technology crucial for medical isotope production.
Prior to that, Dr. de Jong was the Chief Medical Isotope Officer at Canadian Light Source Inc. (CLS), where he oversaw the development and commercialization of the MIP facility dedicated to producing Molybdenum-99 (99Mo) for medical applications. His tenure at CLS was marked by groundbreaking achievements, including the design and commissioning of a 2.9 GeV electron synchrotron, and the development of innovative photo-neutron methods for producing 99Mo.
“Dr. de Jong brings a distinguished background in particle accelerator technology, especially within the pharmaceutical sector. His role will be impactful in leading our efforts to implement a state-of-the-art particle accelerator for radioisotope production,” said Philippe van Put, General Manager of Full-Life Technology Europe. “With his extensive experience in medical isotope production and a proven track record in developing and managing electron accelerator facilities, Dr. de Jong is well-equipped to drive our projects to the next stage of development. His leadership skills, technical prowess, and long-term strategic management of accelerator facilities have earned him international recognition and a place on prestigious committees and projects. We are excited about the fresh perspectives and innovative approaches Dr. de Jong will bring to our team.”
Dr. de Jong has also contributed significantly to international nuclear safety and medical isotope production standards, serving as Chief Scientific Investigator for the International Atomic Energy Agency and holding leadership roles in several international advisory committees.
About Full-Life Technologies:
Full-Life Technologies Limited is an integrated global radiotherapeutics company with a comprehensive approach to the research, development, production, and commercialization of radiopharmaceuticals. Based in Belgium, with additional operations in Germany and China, Full-Life aims to revolutionize radiopharmaceuticals by tackling core issues through innovative research. The company’s team consists of skilled entrepreneurs and scientists with extensive experience in life sciences and radioisotope research.
Read Also : Imagination in a Disrupted Age: Navigating the Future with Curiosity and Empathy
